全文获取类型
收费全文 | 56957篇 |
免费 | 4671篇 |
国内免费 | 171篇 |
专业分类
耳鼻咽喉 | 512篇 |
儿科学 | 1652篇 |
妇产科学 | 1091篇 |
基础医学 | 7475篇 |
口腔科学 | 1000篇 |
临床医学 | 6312篇 |
内科学 | 10906篇 |
皮肤病学 | 827篇 |
神经病学 | 4791篇 |
特种医学 | 2643篇 |
外科学 | 9409篇 |
综合类 | 800篇 |
一般理论 | 57篇 |
预防医学 | 5520篇 |
眼科学 | 1264篇 |
药学 | 4067篇 |
1篇 | |
中国医学 | 56篇 |
肿瘤学 | 3416篇 |
出版年
2023年 | 291篇 |
2022年 | 203篇 |
2021年 | 1050篇 |
2020年 | 663篇 |
2019年 | 1093篇 |
2018年 | 1321篇 |
2017年 | 960篇 |
2016年 | 1046篇 |
2015年 | 1255篇 |
2014年 | 1822篇 |
2013年 | 2547篇 |
2012年 | 3821篇 |
2011年 | 3907篇 |
2010年 | 2177篇 |
2009年 | 1923篇 |
2008年 | 3423篇 |
2007年 | 3662篇 |
2006年 | 3564篇 |
2005年 | 3454篇 |
2004年 | 3194篇 |
2003年 | 3035篇 |
2002年 | 2869篇 |
2001年 | 885篇 |
2000年 | 846篇 |
1999年 | 819篇 |
1998年 | 672篇 |
1997年 | 568篇 |
1996年 | 523篇 |
1995年 | 595篇 |
1994年 | 500篇 |
1993年 | 474篇 |
1992年 | 556篇 |
1991年 | 506篇 |
1990年 | 518篇 |
1989年 | 523篇 |
1988年 | 469篇 |
1987年 | 417篇 |
1986年 | 424篇 |
1985年 | 472篇 |
1984年 | 389篇 |
1983年 | 329篇 |
1982年 | 287篇 |
1981年 | 250篇 |
1980年 | 241篇 |
1979年 | 254篇 |
1978年 | 247篇 |
1977年 | 199篇 |
1976年 | 205篇 |
1975年 | 196篇 |
1974年 | 210篇 |
排序方式: 共有10000条查询结果,搜索用时 136 毫秒
61.
62.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
63.
Interaction effects between the 5‐hydroxy tryptamine transporter‐linked polymorphic region (5‐HTTLPR) genotype and family conflict on adolescent alcohol use and misuse 下载免费PDF全文
64.
Social networks and substance use among at‐risk emerging adults living in disadvantaged urban areas in the southern United States: a cross‐sectional naturalistic study 下载免费PDF全文
65.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
66.
Louise A. Rollins-Smith J. Scott Fites Laura K. Reinert Andrea R. Shiakolas Thomas P. Umile Kevin P. C. Minbiole 《Infection and immunity》2015,83(12):4565-4570
Batrachochytrium dendrobatidis is a fungal pathogen in the phylum Chytridiomycota that causes the skin disease chytridiomycosis. Chytridiomycosis is considered an emerging infectious disease linked to worldwide amphibian declines and extinctions. Although amphibians have well-developed immune defenses, clearance of this pathogen from the skin is often impaired. Previously, we showed that the adaptive immune system is involved in the control of the pathogen, but B. dendrobatidis releases factors that inhibit in vitro and in vivo lymphocyte responses and induce lymphocyte apoptosis. Little is known about the nature of the inhibitory factors released by this fungus. Here, we describe the isolation and characterization of three fungal metabolites produced by B. dendrobatidis but not by the closely related nonpathogenic chytrid Homolaphlyctis polyrhiza. These metabolites are methylthioadenosine (MTA), tryptophan, and an oxidized product of tryptophan, kynurenine (Kyn). Independently, both MTA and Kyn inhibit the survival and proliferation of amphibian lymphocytes and the Jurkat human T cell leukemia cell line. However, working together, they become effective at much lower concentrations. We hypothesize that B. dendrobatidis can adapt its metabolism to release products that alter the local environment in the skin to inhibit immunity and enhance the survival of the pathogen. 相似文献
67.
68.
69.
70.